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Abstract 
Introduction 
Triple negative breast cancer is a breast cancer subtype associated with advanced 
stage at presentation, aggressive tumour biology and poor disease free and overall 
survivals.  It is characterized by negative immunohistochemical staining for the 
oestrogen and progesterone receptors and Her 2 overexpression.  Studies have shown 
an increased prevalence of triple negative breast cancer in young African-American 
women. 
 
Young age at presentation is similarly associated with poor outcomes.  It is not clear if 
young women with breast cancer do poorly because of increased representation of 
aggressive subtypes or genetic differences unique to young women within each subtype. 
 
Methods 
We undertook a retrospective file review to identify triple negative breast cancer cases at 
two breast care units in Johannesburg.  Presentation, treatment and outcomes data 
were collected on the patients at Milpark Breast Care Unit.  A prospective file review and 
telephonic interview were done for further follow up. 
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Results 
There were 275 patients with triple negative breast cancer identified out of 1898 patients 
(14.4%).  The prevalence at Milpark Breast Care Unit was 13.9% and 16.1% at Helen 
Joseph Hospital. 
 
135 patients were further analysed.  Stage at presentation was IIa and IIb in 
approximately half  (47.23%) of the patients.  Patients presented with large tumours - 
57.78% greater than two centimeters, and lymph node positive disease (55.55%).  The 
majority (72.73%) of patients had high-grade, poorly differentiated tumours.  This is 
consistent with studies showing that triple negative breast cancers present with more 
advanced tumours.  There was a non-significant trend for younger patients to present 
with more advanced tumours with more aggressive histology. 
 
The triple negative breast cancer is challenging to manage due to its lack of response to 
steroid blockade and lack of biological therapy. This was reflected in the number of 
patients treated with multimodality therapy.  94.81% of patients had chemotherapy, 
59.26% as neoadjuvant and 40.74% as adjuvant treatment.  There were 93 (68.89%) 
patients treated with radiation therapy.   
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There was a recurrence in 22.96% of patients, with preponderance to lymph node and 
visceral metastases.  Recurrences occurred early, the median was 23.1 months and all 
had occurred within eight years.  Younger patients had more recurrences (32.35%) and 
all occurred within six years.  Stage at presentation and lymph node involvement were 
significantly associated with recurrence. 
 
Complete pathological response to neoadjuvant chemotherapy is associated with 
improved outcomes. The recurrence rate was 1.25% if there was a complete 
pathological response in both the breast and lymph nodes. 
 
The mortality rate was 19.26% and was greater in younger patients, 23.53% for women 
40 years old and younger and 31.82% for women 35 years old and younger.  Mortality 
was significantly associated with stage at presentation and lack of surgery but not lymph 
node positivity. 
 
Conclusion 
The prevalence of triple negative breast cancer in two South African breast care units 
was similar to some studies but less than studies in West and East Africa.  Patients in 
these units, similar to other units, presented at a more advanced stage and had poorer 
outcomes than luminal breast cancers.  Younger patients showed a trend to more 
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advanced presentation and poorer outcomes than older patients within the triple 
negative subtype.  This suggests than the outcomes of young patients cannot be 
explained by preponderance to aggressive subtypes alone. 
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Chapter 1.  Introduction 
 
Breast cancer in women is the second most common cancer in the world and the most 
common cancer among women globally.  Breast cancer is the second highest cause of 
cancer death in women, after lung cancer (1) 411 093 women die of breast cancer a 
year (2).  In sub-Saharan Africa breast cancer is the most prevalent cancer in women 
and since 2008 there has been a 20% increase in the incidence of breast cancer 
worldwide (3).  Breast cancer in women 40 years or younger represents 7 % of all breast 
cancers (4).   
 
 
1. 1 Breast cancer subtypes 
 
In 2000 the Stanford Group described an intrinsic gene subset for breast cancers, 
describing four subtypes of breast cancer according to gene assay of molecular 
markers.  The four subsets were ER positive or luminal, basal-like, Her2 positive and 
normal breast-like (5). Luminal tumours were characterised further and the resulting five 
subtypes used to describe breast cancers were: 
• Luminal A (ER pos, PR pos, Her2 neg,) 
• Luminal B (ER pos, PR pos, Her2 pos) 
• Her2 overexpressing (ER neg, PR neg, Her2 pos) 
• Basal-like (ER neg, PR neg, Her2 neg)  
• Normal breast-like or unclassified (ER neg, PR neg, Her2 neg) (6) 
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The definition of breast cancer subtypes has been refined since the first publication in 
2000.  In clinical practice four subtypes are commonly used.  Luminal A describes an 
oestrogen and progesterone receptor positive, low-grade tumour.  Luminal B is used for 
oestrogen receptor positive tumours that may or may not be progesterone receptor 
positive or Her2 overexpressing and are high grade.  Her2 tumours overexpress Her2 
but are negative for oestrogen and progesterone receptors.  Triple negative breast 
cancers do not express positivity for oestrogen, progesterone or Her2 receptors (7). 
 
Luminal A is the predominant subtype (51.9%) followed by luminal B (27.5%).  Triple 
negative breast cancer prevalence ranges from 10% to 55% depending on the 
population surveyed (8,9).  The prevalence of Her2 overexpressing tumours is 7% (10).   
 
These subtypes have been linked to clinical presentation and outcomes.  The luminal 
tumours have the best outcomes and patients with luminal A breast cancer have the 
best prognosis. Patients with either Her2 overexpressing or basal-like subtypes have the 
worst overall survival. The outcomes have changed for Her2 overexpressing breast 
cancer with recent advances in targeted therapies for e.g. trastuzumab (6). 
 
It has become more apparent that oestrogen receptor positive and receptor negative 
breast cancers differ at a molecular level (11).   Kramangar et al (2), suggest that there 
should be a shift in breast cancer models to stratify breast cancer as either oestrogen 
receptor positive or negative. They describe two distinct types of breast cancer – 
oestrogen negative cancers, which have increasing prevalence in premenopausal 
women, are aggressive, have unusual morphology and an association with BRCA 1.  
These cancers have a higher incidence in low risk populations such as native Japanese 
women, and are associated with a higher mortality rate.  The second type of breast 
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cancer is oestrogen receptor positive, which is more prevalent globally and 
predominantly affects postmenopausal women.  It behaves in a less aggressive manner, 
with better differentiated histology and an association with BRCA 2 (2). 
 
The recommended definition of breast cancer subtypes are based on 
immunohistochemical (IHC) tests that distinguish immunoreactive cells (12). The 
previously defined threshold was more than 10% immunoreactive cells, and this was 
used in a number of clinical trials and epidemiological studies, however nowadays 
oestrogen and progesterone receptor negative breast cancers are those that express 
less than 1% immunoreactive cells (1).   
 
1. 2 Triple negative breast cancer 
 
Triple negative breast cancer is a heterogeneous group of tumours. The defining 
features are a lack of expression of oestrogen and progesterone receptors, and lack of 
overexpression of the Her2 gene (13). Triple negative breast cancer is a clinical term 
that encompasses the basal-like and normal breast tissue-like cancers described by the 
Stanford group.  The terms are sometimes used interchangeably but are not completely 
synonymous (6).  
 
There is relatively uniform 20-30% discordance between triple negative breast cancer 
and basal-like breast cancer (14).  Triple negative is often used as a surrogate for the 
prevalence of basal-like breast cancer in a population.  Bauer et al (15), found that in a 
population-based study triple negative tumours can be used as a surrogate marker for 
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basal-like breast cancer as the proportion of basal-like to triple negative breast cancers 
corresponded with incidences reported in other studies.  
 
It is important to note that the triple negative breast cancer subtype describes a 
heterogeneous group of breast cancers.  Ongoing research has further defined triple 
negative breast cancer into six subgroups and used extensive immunohistochemical 
testing and cluster analysis to define their characteristics (16).  These subgroups differ in 
presentation, tumour grade and survival outcomes (17). The basal-like phenotype 
comprises the majority of triple negative breast cancers, however other molecular 
subtypes exist: these include the Her2 overexpressing group, luminal A, luminal B, 
claudin-low, and a few normal-like tumours (18).  
 
Other types of tumor classified as triple negative breast cancer include carcinomas 
morphologically designated as of no specific type (salivary gland-like carcinomas 
(particularly the adenoid cystic carcinomas and myoepithelial carcinomas), lobular, 
and/or mixed features.  Some papillary and secretory-like carcinomas may also be 
regarded as triple negative disease (13). 
 
There is also a link between triple negative breast cancer and the BRCA1 mutation with 
approximately 70% BRCA1 mutation breast cancers presenting as triple-negative.  A 
number of histopathological features including genomic instability and DNA repair effects 
are shared by BRCA1- associated tumours and triple negative breast cancers (19).  
 
There has been a surge of interest and research into triple negative breast cancer over 
the past few years.  This is due to the unique presentation and management of these 
patients.  Triple negative breast cancer is characterised by high cell proliferation, poor 
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cellular differentiation, many recurrent copy number imbalances, and, often mutations in 
the TP53 tumour suppressor gene (14).  Triple negative breast cancers present at an 
earlier age and have large tumour size, high histological and nuclear grade at 
presentation (20). Triple negative tumours are also more likely to present in the two 
years between screening mammograms (21).  
 
Patients with triple negative breast cancer have lower disease free survival and higher 
mortality rates than other breast cancers.  Studies have demonstrated 40.4% all cause 
mortality and 30.8% breast cancer specific mortality for triple negative breast cancer as 
opposed to 21.3% all cause mortality for luminal A tumours (22).  The five year overall 
survival and five year disease free survival is 81-84% and 79-84% for triple negative 
tumours compared to 94-96% and 90-95% for luminal A breast cancer (20). 
 
Studies have also shown that not only is the recurrence rate higher in triple negative 
breast cancer (30.8% vs. 14.8% in luminal A), the peak time of recurrence is earlier, 
typically within two to three years after treatment with poor post recurrence survival (23).   
Triple negative breast cancer is more prone to blood borne metastases and 13% of 
patients will have distant metastases two years after diagnosis with preponderance to 
visceral and brain metastases (24).     
 
1. 2. 1  Basal-like breast cancer 
 
Basal-like breast cancer is one of the genetic subtypes described by the Stanford group.  
It is characterised on immunohistochemistry by positive staining for cytokeratins of the 
basal layers of the duct epithelium and increased expression of proliferative markers.  
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Genetic studies of basal-like breast cancer show decreased expression of the hormone 
receptor cluster genes and increased expression of the proliferative cluster.  This is in 
keeping with the poor differentiation of most basal-like tumours (14). 
 
 
Basal-like breast cancer is a component of the triple negative breast cancers, and a 
more homogenous group. There is still, however no internationally accepted definition 
for basal-like breast cancers and how best to define these tumors is a matter of 
controversy and ongoing debate (21).  A British group compared three methods of 
defining basal-like breast cancer – morphology, immunohistochemistry and 
transcriptional profiles.  There were 116 basal-like breast cancers of which 13 were 
identified by all three methods (25). 
 
The concept of a distinct aetiology is supported by a study looking at the risk factors 
associated with basal-like tumours.  It was found that younger age at menarche and 
shorter duration of breast-feeding were strong risk factors, which is similar to the other 
breast cancer subtypes.  In contrast to luminal A tumours, increased parity, younger age 
at first pregnancy, and suppression of lactation are also risk factors for basal-like 
tumours.  Increased BMI and waist-hip ratio are associated with basal-like breast cancer, 
especially in pre-menopausal women.  This is unlike luminal tumours where obesity is a 
risk factor in only post-menopausal women.  Basal-like tumours were especially 
associated with an increase in adiposity since childhood (26). 
 
1. 2. 2 Normal breast like breast cancer 
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The triple negative breast cancers that are not basal-like are a subtype described by 
Stanford Group as unclassified or normal breast like.  These cancers do not stain 
positive for the basal cytokeratins but have high expression of the genes characteristic of 
basal epithelial and adipose cells and low expression of the genes characteristic of 
luminal epithelial cells (5).  
 
Studies looking at the genetic profile of these cancers have described a non-
homogeneous group with different presentations and outcomes (27).  Groups have 
described six subgroups of triple negative breast cancer (16). 
 
1. 3 Incidence and prevalence 
 
Epidemiological studies have shown that the incidence of triple negative breast cancer is 
10 to 20 % (15).  There is, however, great variation amongst populations.   
 
Numerous studies have shown an increased prevalence of triple negative breast cancer 
in premenopausal African American women. The Carolina Breast Cancer Study was one 
of the first published population based studies investigating the incidence of basal-like 
breast cancer, which they found to be 20-26% of all breast cancer.  The incidence of 
basal-like tumours in African American women was 20-26% vs. 16% in non-African 
American women.  Furthermore they demonstrated an increased prevalence in young 
women, with a 24% incidence in premenopausal women vs. 15% in postmenopausal 
(28). 
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The Carolina Breast Cancer Study showed an incidence of basal-like breast cancer of 
16%, 56% luminal A, 10% luminal B, 8% Her2 overexpressing and 10% unclassified, 
thus triple negative cancers were 26% (28). In contrast a study amongst Japanese 
women showed an incidence of 10% of triple negative breast cancer (29), and in 
Sweden the incidence was 12% (20). 
 
1. 4 The role of ethnicity 
 
Early breast cancer studies of prevalence in triple negative breast cancer demonstrated 
a disproportionately high prevalence in African-American women; studies such as 
Bowen et al (30), showed an increased prevalence of triple negative breast cancer in 
young black British women (22% black women and 15% white women).  Huo et al (9), 
studied the prevalence of triple negative disease in Nigeria and Senegal and showed an 
incidence of 55%.  This marked prevalence of triple negative breast cancer may be 
linked to the increased incidence in African American women as many African 
Americans are of West African descent (31).   
 
This significantly high prevalence in African women led to a number of studies 
investigating the prevalence of breast cancer subtypes in African populations.  Incidence 
rates ranged from 16.5% in Morocco (32), 27% in Kenya (33) to 46% in Mali (34).  All 
studies demonstrate younger age and more advanced stage at presentation.   
 
It has been postulated that an increased prevalence of an aggressive triple negative 
subtype partly accounts for the poorer outcomes in young African American women (35).  
A study looking at breast cancer survival and ethnicity found that African American 
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ethnicity was an independent predictor of adverse outcome with a 22% excess risk of 
death from all causes (36).  In 2006 Smigal et al (37), researched trends in breast 
cancer in the USA from 1995 to 2002 and showed that for women under the age of 35 
the incidence of breast cancer was higher in African American women compared to 
Caucasian women. The study also showed that despite the overall incidence of breast 
cancer being highest in Caucasian women, African American women had 37% higher 
death rates.   
 
1. 5 What is the prevalence in South Africa? 
 
Kramangar et al (2), looked at patterns of cancer incidence, mortality and prevalence 
globally and found a lack of data to describe temporal trends in Africa.  A Pub Med 
search in 2010 resulted in a limited number of studies investigating basal-like or triple 
negative breast cancer in Africa.  Subsequently there have been a number of 
publications documenting prevalence rates of triple negative breast cancer in Africa – 
but all are from North, East and West Africa.  There is still a dearth of publications from 
southern Africa. 
 
In 2004 Walker et al (38), reviewed breast cancer trends in South Africa and found a low 
incidence compared with developed nations – 15.1 vs. 40-89 per 100 000.  They 
reported that South African black women presented an average of ten years earlier with 
more advanced disease.  They note that changes in lifestyle have decreased the 
protective factors such as late menarche and high parity, which has led to increasing 
incidence in black South African women.  Breast cancer has overtaken cervical cancer 
as the most common cancer in women in South Africa between 1993 and 1995, 
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however, the national cancer registry published in 2007 may underestimate the more 
recent incidence of breast cancer in South Africa (39).   
 
Research into tumour biology and behaviour in a low to middle income countries such as 
South Africa, adds valuable information to our understanding of breast cancer in that 
country.  Many of the recommendations guiding management of breast cancer are 
derived from research undertaken in high-income countries, which may not be applicable 
elsewhere.  Furthermore there are differences in breast cancer subtypes in different 
populations but these may not explain the differences in outcomes (40).  
 
 
1. 6 Management of triple negative breast cancer 
 
The mainstay of the management of triple negative breast cancer involves the use of 
systemic chemotherapy agents as its unique biology and lack of conventional targets 
and receptors renders hormonal therapy ineffective.  Thus chemotherapy is the mainstay 
of treatment, usually anthracycline and taxane based regimens (19).  Poor disease free 
outcomes are seen especially if the patient has a poor response to chemotherapy due to 
the dearth of other treatment options (41).  The lack of targeted therapy (both hormonal 
and biological) has driven research into alternative chemotherapy regimens such as 
carboplatins (42).  These have shown improved response rates with insufficient 
evidence to support universal use. 
 
Triple negative tumours have traits of DNA damage repair defects possibly due to a 
disruption in the BRCA 1 pathway.  The genetic link between triple negative tumours and 
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BRCA 1 has, with further study, led to possible targeted therapy for both (23).   The ideal 
would be to find a targeted therapy such as trastuzumab, which has reduced disease 
recurrence by 52% in Her2 overexpressing breast cancers (22).   
 
PARP - poly (ADP-ribose) polymerase – is a nuclear enzyme which plays a critical role 
in the response to DNA damage.  Inhibitors of PARP are used to enhance the effects of 
cytotoxic agents such as anthracyclins and radiotherapy.  PARP inhibitors were 
originally developed for BRCA 1 and BRCA 2 tumours, and it was thought that the 
BRCAness of triple negative breast cancers meant that they would also benefit from 
PARP inhibition (43).  Early reports of phase III trials; however, failed to show any 
significant benefit for PARPs in triple negative breast cancer (19).   
 
The failure of PARPs and the persistently poor outcomes fuels interest in targeted 
therapy for triple negative breast cancer.  New targets are endothelium growth factor 
receptor (EGFR), checkpoint kinase 1, mammalian target of rapamycin (mTOR) and a 
host of others.  The search for effective target therapy has resulted in substantial 
research in the molecular pathways of triple negative breast cancer (44). 
 
 
1. 7 Breast cancer in young women 
 
Breast cancer in young women is becoming a significant health care concern since 7% 
of patients in the developed world and 25% in the developing world are diagnosed with 
breast cancer below the age of 40 (45).  The majority of breast cancers still present in 
older, post menopausal women but there is great interest in breast cancer in women 
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younger than 40.  These younger patients have a more advanced stage at presentation 
and poorer outcomes such as disease free survival and overall survival.   
 
Young women have higher mortality and recurrence rates than older women, with up to 
four times increased local recurrence in women younger than 45.  Younger patients are 
more likely to have large tumours and advanced stage at presentation.  Tumours in 
younger women are more likely to be grade III, steroid receptor negative, have 
lymphovascular invasion and positive lymph node disease (46). 
 
There are two schools of thought to explain the documented poor outcomes in younger 
women.   The question is whether breast cancer diagnosed at a young age has a unique 
biology or is a representative of an increased incidence of aggressive subtypes (47).   
Studies have documented an increased representation of aggressive subtypes such as: 
basal-like, unclassified and Her2 overexpressing in young women (48).  It has been 
postulated that it is a preponderance to aggressive subtypes that is responsible for poor 
prognosis in young women.  Authors such as Jenkins et al have concluded that age is 
not an independent prognostic factor in breast cancer (49).  Adherents of this theory 
state that treatment should be guided by subtype biology and performance status and 
not age (50). 
 
There are, however, conflicting studies demonstrating, using multivariate analysis, age is 
an independent predictor of outcome in breast cancer.   These include studies based on 
microarray data, which have shown increased proliferation-related prognostic gene 
signatures in young women (47,51). This data implies that there is unique biology of 
breast cancer in young women regardless of breast cancer subtype.  This theory is 
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supported by studies that have shown a difference in outcome according to age within 
the triple negative subgroup of breast cancers (52). 
 
It is important to define how age at diagnosis impacts breast cancer outcomes as this 
may guide treatment.  In 2001 the St Gallen Consensus Conference included age at 
presentation as an indication for chemotherapy.  Recent studies have highlighted the 
importance of the unique breast stroma in young women, showing that this 
microenvironment is very responsive to growth factor stimulation, which could promote 
aggressive growth.  This stroma is a potential target for treatment (47). 
 
The definition of a 'young woman' in breast cancer research varies, with most articles 
referring to women under either age 35 or 40 years as 'young', however under 45 has 
also been used (53).  The lack of a standard definition of what is ‘young’ in breast cancer 
is challenging especially as there appears to be a crossover in racial and survival 
differences after the age of 40. A cutoff of age 40 may allow more focused and accurate 
assessment of the differences in young and old patients with breast cancer (54).  A 
literature review in 2004 found that the group of patients in whom age was an 
independent risk factor for recurrence was women aged 35 to 40 and younger (55). 
 
The MD Anderson Cancer Centre group analysed their patients according to age and 
found age younger than 40 was significantly associated with poor prognosis even on 
multivariate analysis (51,52).    
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1. 8 Hypotheses 
 
1) In patients with triple negative breast cancer women 40 years old and younger 
have different presentation and outcomes to women older than 40 years. 
 
2) The proportion of triple negative breast cancer is higher in a South African 
population than North American or European populations.   
 
3) Disease free survival and mortality of triple negative breast cancer in a South 
African Breast Care Unit is similar to international trends. 
 
 
1. 9 Aim 
 
To document the frequency, presentation and outcomes of South African patients who 
present with triple negative breast cancer according to age. 
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1. 10 Objectives 
 
1) To determine the prevalence of triple negative breast cancer at both Milpark and 
Helen Joseph Hospital Breast Care Units. 
 
2) To determine the disease free survival and mortality of triple negative breast 
cancer at Milpark Hospital Breast Care Unit. 
 
3) To compare presentation and outcomes of patients with triple negative breast 
cancer according to age. 
 29 
Chapter 2.  Methods 
 
This study consisted of two components - a retrospective file review and prospective file 
review and telephonic interviews.  The file reviews were conducted at the Netcare 
Milpark Breast Care Centre and the Helen Joseph Hospital Breast Unit.  Both units are 
in Johannesburg and affiliated with the University of the Witwatersrand.   
 
Ethics approval was obtained from the University of the Witwatersrand Ethics Committee 
as well as approval from both the Netcare Milpark and the Helen Joseph Hospitals.   
 
At the Netcare Milpark Breast Care Centre all files of patients seen between 1 January 
2000 and 31 June 2010 were reviewed. Where possible, missing data were collected 
from the pathologist or treating oncologist; this was done by file review, and telephonic 
and email request. 
 
Once all the patients at the Netcare Milpark Breast Care Centre were identified, follow 
up was assessed until 31 December 2012.  Reviewing the files of all identified patients 
and telephonic interviews collected the follow up information.  The telephonic interviews 
were conducted according to a predetermined questionnaire, and verbal consent was 
obtained prior to the interview.   
 
The files of patients seen at the Helen Joseph Hospital Breast Unit were reviewed for 
data regarding the number of patients with breast cancer and their histological subtype.  
Where the histology was not available from the file, the National Health Laboratory 
Service computer records were searched for missing data. 
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Patients were deemed to have triple negative breast cancer if the immunohistochemistry 
testing for oestrogen, progesterone receptors and Her2 were negative.  The threshold 
limit for immunohistochemical testing was reviewed and revised in 2009 by ASCO.  Prior 
to this a result of less than 10% reaction was negative.  The new threshold for a negative 
test is less than 1% (56).  In this study the threshold in place at the time of testing was 
used.    
 
 Immunohistochemical testing for Her2 status provides three possible results: 1+, 2+ and 
3+.  1+ is considered a negative result, 3+ a positive result and 2+ is equivocal.  If the 
Her2 status was equivocal, in-situ hybridisation testing was performed to confirm the 
presence or absence of Her2 over-expression (57).  This is similar to a study done at 
MD Anderson Cancer Centre (51). 
 
Her2 was first described in 1985 (58) and testing only became routine in  the late 1990s.  
Testing was not, however, universally performed especially if trastuzumab was not 
available, thus 30 patients from Milpark Breast Care Centre and 135 from Helen Joseph 
were excluded because no Her2 result as available.  A further 26 patients at Milpark 
Breast Care Centre and 23 from Helen Joseph were excluded from the study when the 
Her2 testing was equivocal and a confirmatory in situ hybridisation test had not been 
done.   
 
In cases where the receptor testing of the core biopsy and the final surgical specimen 
differed, the surgical specimen was used if the patient had not had neoadjuvant 
chemotherapy.  If the patient had neoadjuvant chemotherapy and there was minimal 
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tumour response the receptor status of the surgical specimen was used.  If there had 
been a significant response the receptor status of the core biopsy specimen was used.  
These cases were reviewed at the Milpark Breast Care Unit multidisciplinary meeting, 
with the pathologist involved, or the treating oncologist. 
 
In patients where the histology was unclear e.g. triple negative disease in a lobular 
breast cancer, a pathologist from the Milpark Hospital Breast care Unit multidisciplinary 
team reviewed the specimen.  Alternatively the original pathologist was asked to review 
the specimen.  A number of cases were found to be ductal adenocarcinoma on review. 
 
The breast cancer specimens were classified according to the Nottingham modification 
of the Scarff-Bloom-Richardson score, which grades tumours from 3-9.  A score of 3-5 is 
low grade, 6-7 is intermediate and 8-9 is high grade (59).  It has been clearly shown that 
the histologic grading of invasive breast carcinoma, in particular the Nottingham 
modification of the Scarff-Bloom-Richardson (NSBR) grading scheme provides 
significant prognostic information (60). 
 
Nuclear grading was also assessed and graded according to Fisher’s modification of 
Black’s nuclear grade. Nuclear grade is considered to be one of the most important 
prognostic factors in breast cancer (61).  The NSBR and the nuclear grade were then 
used to assign patients in the study a score from 1 to 3.   1 was poorly differentiated, 2 
moderately differentiated and 3 well differentiated. 
 
The histologic specimens were assessed at a number of laboratories over a long period 
of time and the reporting of specimens was not uniform.  Where possible any 
discrepancies or missing data was clarified with the laboratory.  The patients where the 
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histology was not clear were discussed at the multidisciplinary team meeting and a 
consensus decision taken. 
 
Stage at presentation and after neoadjuvant therapy was classified according to the 
seventh edition of the American Joint Committee on Cancer staging manual (62). 
 
Response to neoadjuvant chemotherapy was assessed as present or absent.  Three 
modalities were used to assess response – clinical, radiological and pathological. 
Response in the breast was present if the size of the tumour decreased from the pre-
chemotherapy assessment or there was histological evidence of a response to 
chemotherapy.  Axillary nodes had responded if the number of involved nodes had 
decreased or if there was evidence of a response to chemotherapy. 
 
Disease recurrence was noted clinically or radiologically.  Where possible tumour 
recurrence was confirmed with a biopsy for either cytology or histology.  In the case of 
visceral metastases e.g. brain or liver, biopsies were often not done, and the diagnosis 
was made on imaging. 
 
Disease free survival was defined as the time in months from date of diagnosis to the 
date of diagnosis of recurrence (local, regional or distant), date last seen or death.  
Overall survival was defined as the time in months from the date of diagnosis to the date 
of last follow up or death from any cause (51). 
 
Patients in our study were analysed in two major age groups- 40 years or younger and 
older than 40 years old.  To assess whether there were further differences, women 35 
years old and younger were assessed separately. 
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2. 1 Inclusion Criteria 
 
• Women older than 18 years old. 
• Women with invasive breast carcinoma. 
• Patients for whom the results of oestrogen receptor, progesterone receptor and 
Her2 testing were known. 
 
2. 2 Exclusion Criteria 
 
• Patients for whom their receptor status could not be confirmed. 
• Discrepancies in histology that could not be resolved. 
• Missing data. 
 
2.3 Ethics 
 
The first component of the study was a retrospective review and there was no change to 
the management of patients.  The second, prospective component extended the follow 
up of patients, and again no changes were made to management.  Demographic data 
were collected but kept anonymous.  Data were kept anonymous for analysis. 
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A submission made to the University of the Witwatersrand Human Research Ethics 
Committee in May 2010 was approved. The clearance certificate number is M10543. 
(Appendix 2) 
 
A second application was made to the ethics committee in May 2013 for follow up data 
collected by file review and telephonic interview. The second clearance certificate is 
M130545.  (Appendix 3) 
 
 
2.4 Data analysis 
 
All data were entered into Excel spreadsheets. 
For the patients at Milpark Breast Care Centre, the following variables were collected:  
age, race, stage at presentation, size of tumour, axillary involvement, distant 
metastases, neoadjuvant and adjuvant treatment, surgery, response to treatment, 
recurrence and death.  Where appropriate, variables such as age were categorised 
before analysis. 
 
Statistical analysis was done with Strata.  Significance of results was determined with 
either a Chi-squared or Fischer exact test.  Patients were stratified by age: 40 years old 
and younger, and older than 40 years 
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2.5 Benefit 
 
• To further knowledge about triple negative breast cancer and breast cancer in 
young women.  
• To define a South African public health issue. 
• To elucidate any differences between older and younger women with the same 
breast cancer subtype. 
• To aid in outreach programmes to inform and educate the community. 
• To be used as a tool to raise funds for awareness campaigns. 
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Chapter 3.  Results 
 
In this study 2516 files were reviewed, 1583 at Milpark Breast Care Centre and 933 at 
Helen Joseph Hospital.  618 patients were excluded, 176 from Milpark Breast Care Unit 
and 442 from Helen Joseph Hospital.   
 
The patients from Milpark were excluded as histology was not available in 37 patients, 
receptor status was not clear or conflicting in 83 results, and in 56 patients the Her2 
status could not be determined. The reason for 284 of the exclusions from Helen Joseph 
Hospital was that the receptor status of the breast tumour could not be determined.  A 
further 158 patients were excluded as an immunohistochemistry result for Her 2 
overexpression was not available or equivocal. 
 
It was not possible to collect data regarding presentation, treatment and outcomes on 
the 79 patients identified with triple negative breast cancer at Helen Joseph.  Of the 196 
patients identified at Milpark Breast Care Centre, 61 were excluded because of in situ 
disease or no primary (7) and missing data (54). 
 
Follow up of patients was determined from date of diagnosis to date of death or date last 
seen.  The range is 1 to 121 months with a median of 45 months. 
 37 
Figure 1: Consort diagram 
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3. 1 Incidence of breast cancer subtypes 
 
A total of 275 patients with triple negative breast cancer were identified, 196 at Milpark 
Breast Care Centre and 79 at Helen Joseph Hospitals.  Triple negative breast cancers 
comprised a greater percentage of the total number of breast cancers at Helen Joseph 
Hospital (16.1%) than at Milpark Breast Care Centre (13.9%).  Luminal B and Her2 over 
expressing tumours were similarly present in greater proportion at Helen Joseph 
Hospital than Milpark Breast Care Centre.  
 
Table 1. Patients at Milpark and Helen Joseph Hospital Breast Care Units 
according to breast cancer subtype. 
 
 
 
 
Milpark 
(percentage 
Milpark total) 
n=1407 
Helen Joseph 
(percentage Helen 
Joseph total) 
n=491 
Total 
 
 
n=1898 
Total 1407  491 1898 
Luminal A 909 (64.6%) 260 (52.9%) 1169 (61.6%) 
Luminal B 150 (10.6%) 80 (16.3%) 220 (11.6%) 
Her 2 over 
expressing 
152 (10.8%) 72 (14.7%) 224 (11.8%) 
Triple negative 196 (13.9%) 79 (16.1%) 275 (14.4%) 
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3. 2 Age and menopausal status at presentation 
 
The patient’s age at presentation could be analysed in 135 patients.  Women 40 years or 
younger comprised 25.19% of the sample and women older than 40 years were 74.81%.  
In the cohort over half (57.8%) were postmenopausal. 
 
Table 2. Age at presentation 
Total 135  
Very young (≤35) 22 16.30% 
Young (≤40) 34 25.19% 
Older (>40) 101 74.81% 
 
 
 
17.04%
8.148%
74.81%
Very Young Young
Older
Figure 1: Age distribution of the patients
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Table 3. Age ranges of patients 
 
 
Table 4. Menopausal status at presentation. 
 
 
 
 
  Standard deviation 
Very young (≤35)   
Mean 30.4 4.1 
Median 31  
Range 18 - 35  
   
Young (≤40)   
Mean 34.1 5.1 
Median 33  
Range 18 – 40  
   
Older (>40)   
Mean 57.7 11.4 
Median 57  
Range 41 – 108  
   
Total   
Mean 51.3 14.6 
Median 54  
Range 18 - 108  
Total 135  
Premenopausal 49 36.30% 
Perimenopausal 8 5.93% 
Postmenopausal 78  57.78% 
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3. 3 Stage and tumour characteristics at presentation 
 
The 135 patients were analysed for stage at presentation.  Stages IIA and IIB accounted 
for almost half (47.23%) of stage at presentation. 
 
Table 5. Tumour characteristics and stage at presentation. 
 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Stage     0.518 
IA 3 (13.6%) 6 (17.7%) 21 (20.8%) 27 (20.0%)  
IB 0 0 2 (2.0%) 2 (1.5%)  
IIA 5 (22.7%) 8 (22.8%) 23 (23.0%) 31 (23.5%)  
IIB 9 (40.9%) 12 (35.3%) 20 (19.8%) 32 (23.7%)  
IIIA 3 (13.6%) 4 (11.8%) 16 (15.8%) 20 (14.8%)  
IIIB 2 (9.1%) 4 (11.8%) 14 (13.9%) 18 (13.3%)  
IV 0 0  5 (5.0%) 5 (3.7%)  
      
      
Early breast cancer 20 (91.0%) 30 (88.2%) 82 (81.2%) 112 (83.0%)  
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 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Tumour size      0.352 
T1 – (<2cm) 5 (22.7%) 7 (20.6%) 31 (30.7%) 38 (28.1%)  
T2 – (2-5 cm) 10 (45.5%) 17 (50.0%) 45 (44.6%) 62 (45.9%)  
T3 – (>5cm) 5 (22.7%) 6 (17.7%) 10 (9.9%) 16 (11.9%)  
T4 (skin/chest 
wall/both)  
2 (9.1%) 4 (11.8%) 15 (14.9%) 19 (14.1%)  
      
Lymph node 
involvement 
    0.276 
N 0 9 (40.9%) 15 (44.1%) 45 (44.6%) 60 (44.4%)  
N 1 12 (54.6%) 17 (50.0%) 40 (39.6%) 57 (42.2%)  
N 2 and N 3 1 (4.6%) 1 (2.9%) 16 (15.8%) 18 (13.3%)  
Total positive 14 (63.6%) 19 (52.9%) 56 (55.4%) 75 (55.6%)  
      
Grade      
1 1 (4.6%) 2 (5.9%) 5 (5.8%) 7 (5.8%)  
2 4 (18.2%) 8 (23.5%) 18 (20.7%) 26 (21.5%)  
3 17 (77.3%) 24 (70.6%) 64 (73.6%) 88 (72.7%)  
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 3. 4 Surgery for the breast primary 
 
Surgery remains a key component in the management of breast cancer and the majority 
of patients in this study underwent surgery.  The reasons why patients did not have 
surgery were varied and included patient choice, the presence of metastatic disease and 
the patient’s medical fitness for surgery.  
 
These results demonstrate the greater proportion of younger women who required more 
extensive surgery. 
 
Table 6. Surgical management 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Surgery     0.172 
BCS 8  15  53  68   
Mastectomy 14  19  42  61   
None 0 0 6  6   
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50.37% 
45.19% 
4.444% 
BCS Mastectomy 
None 
Figure 3: Type of Surgery 
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3. 5 Neoadjuvant and adjuvant therapy 
 
The majority of patients in this study had chemotherapy either as neo-adjuvant or 
adjuvant treatment and seven patients had both.  
 
Table 7. Neoadjuvant and adjuvant treatment 
 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Neoadjuvant  chemotherapy     0.120 
Yes 16 (72.7%) 24 (70.6%) 56 (55.5%) 80 (59.3%)  
No 6 (27.3%) 10 (29.4%) 45 (44.5%) 55 (40.7%)  
      
Adjuvant therapy     0.371 
Yes 20 (90.9%) 31 (91.2%) 86 (85.2%) 117 (86.7%)  
No 2 (9.1%) 3 (8.8%) 15 (14.8%) 18 (13.3%)  
      
Adjuvant chemotherapy      
yes 6 (27.3%) 10 (29.4%) 45 (44.6%) 55 (40.7%)  
      
Adjuvant radiation therapy      
yes 16 (72.7%) 24 (70.6%) 69 (68.3%) 93 (68.9%)  
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In the group of patients who had adjuvant radiation therapy we assessed the type of 
surgery those patients had had.  This was to determine whether the major indication for 
adjuvant radiation therapy was breast-conserving surgery. 
 
Table 8. Radiation therapy by type of surgery 
 
 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Neoadjuvant and adjuvant 
chemotherapy 
     
Yes 2 (9.1%) 3 (8.8%) 4 (4.0%) 7  (5.2%)  
      
All patients chemotherapy      
Yes 20 (90.9%) 31 (91.2%) 97 (96.1%) 128 (94.8%)  
 Very young 
(<35) 
n=16 
Young  
(≤40) 
n=24 
Older  
(>40) 
n=69 
All 
 
n=93 
Radiation therapy      
BCS 6 (37.5%) 11 (45.9%) 45 (65.2%) 56 (60.2%) 
Mastectomy 10 (62.5%) 13 (54.1%) 24 ( 34.8%) 37 (39.8%) 
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3. 6 Multimodality treatment 
 
Table 9. Modalities of treatment 
 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
     
Surgery  22 (100%) 34 (100%) 95 (94.1%) 129 (95.6%) 
Surgery alone 2 (9.1%) 2 (5.9%) 3 (3.0%) 5 (3.7%) 
Chemotherapy 
alone 
0 0 3 (3.0%) 3 (2.2%) 
Radiation 
therapy alone 
0 0 0 0 
Surgery and 
chemotherapy 
20 (90.9%) 31 (91.2%) 91 (90.1%) 122 (90.4%) 
Surgery and 
radiation therapy 
16 (72.7%) 24 (70.6%) 70 (69.3%) 93 (68.9%) 
Chemotherapy 
and radiation 
therapy 
0 0 3 (3.0%) 3 (2.2%) 
Three modalities 16 ( 72.7%) 23 (67.7%) 68 (67.3%) 91 (67.4%) 
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Breast cancer is a complex disease with many factors that determine management and 
outcome.  It is recognized that breast cancer should be treated in a multidisciplinary 
environment with multiple modalities of management (63). It is a reflection of this that the 
majority of patients in this study (67.41%) had management that involved surgery, 
chemotherapy and radiation treatment.  The patients 35 or younger were especially 
likely to have multimodality treatment (72.73%) because of a number of poor prognostic 
features. 
 
 
 
 
9.63%
37.04%49.63%
3.704%
Chemotherapy Radiation
Chemo & Radiation Neither Chemo nor Radiation
Figure 3: Chemotherapy/Radiation
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3.7 Response to neoadjuvant chemotherapy 
 
The 80 patients who had neoadjuvant chemotherapy were assessed for their response 
to chemotherapy and the rates of complete pathological response. 
 
Table 10. Response to neoadjuvant chemotherapy 
 
 
 
 
 
 
 Very young 
(<35) 
n=16 
Young  
(≤40) 
n=24 
Older  
(>40) 
n=56 
All 
 
n=80 
p value 
 
 
      
Response to 
neoadjuvant treatment 
    0.254 
Yes  15 (93.75%) 22 (91.67%) 51 (91.07%) 73 (91.25%)  
      
CPR breast 9 (56.25%) 11 (45.83%) 18 (32.14%) 29 (36.25%)  
CPR nodes 3 (18.75%) 4 (16.67%) 9 (16.07%) 13 (16.25%)  
CPR breast and nodes 3 (18.75%) 3 (12.75%) 8 (14.29%) 11 (13.75%)  
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3.8 Recurrence of triple negative breast cancer 
 
Triple negative breast cancer is recognized as a risk factor for recurrence of breast 
cancer and recurrence within the first two years after diagnosis (64). 
 
Table 11. Breast cancer recurrence 
 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Recurrence     0.215 
Total 8  11  20  31   
Breast 3  4  5  9   
Lymph nodes 0 1  4  5   
Distant 
metastases 
3  4  7  11   
Breast and lymph 
nodes 
1  1  2  3   
Breast and distant 
metastases 
0 0 1  1   
Lymph nodes and 
distant 
metastases 
1  1  1  2   
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 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Recurrence 
outside the breast 
5  7  15  22  
 
Data on time from diagnosis to recurrence data was available for 30 of the 48 
recurrences.   The range was wide, from 4.4 to 92.8 months, but patients 40 years or 
younger had all recurred within 75 months.   
 
Table 12. Time to recurrence in months 
 
 Very young 
(<35) 
n=8 
Young 
(≤40) 
n=10 
Older 
(>40) 
n=20 
All 
 
n=30 
     
Time to 
recurrence 
    
Range 4.5 – 74.6 4.5 – 74.6 4.8 – 92.5 4.5 – 92.5 
Mean 26.8 28.5 23.9 24.8 
Median 19.5 24.3 21.3 23.1 
Standard 
deviation 
25.6 23.1 19.4 20.4 
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Table 13. Breast cancer recurrence according to stage at presentation 
 
 IA 
 
n=27 
IB 
 
n=2 
IIA 
 
n=31 
IIB 
 
n=32 
IIIA 
 
n=20 
IIIB 
 
n=18 
IV 
 
n=5 
p value 
        0.12 
Breast cancer relapse 2 2  7  7  8  7  0  
No breast cancer 
relapse 
25  0 24  25  12  11  5   
 
 
Table 14. Breast cancer recurrence according to lymph node positivity at 
presentation 
 
 Lymph node 
negative 
 
n=60 
Lymph node 
N1 
 
n=57 
Lymph node 
N2 and N3 
 
n=18 
All 
 
 
n=135 
p value 
     0.008 
Breast cancer relapse 7  20  6  33   
No breast cancer relapse 53  37  12  102   
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 3. 9  Response to neoadjuvant chemotherapy and 
recurrence 
 
Response to chemotherapy is been shown to have an impact on outcomes in triple 
negative breast cancer.  Data is available for 80 patients who received neo-adjuvant 
chemotherapy.  
 
Table 15. Recurrence in patients treated with neoadjuvant chemotherapy 
 
 Very young 
(<35) 
n=16 
Young  
(≤40) 
n=24 
Older  
(>40) 
n=56 
All 
 
n=80 
     
Recurrence in patients 
treated with neoadjuvant 
chemotherapy 
5  7  19  26 
Median time to recurrence in 
months 
11 14.9 18.2 18.2 
     
Recurrence in patients with 
CPR in breast 
3  3  4  7  
Median time to recurrence in 
months 
24.5 24.5 19 27.2 
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 Very young 
(<35) 
n=16 
Young  
(≤40) 
n=24 
Older  
(>40) 
n=56 
All 
 
n=80 
     
Recurrence in patients with  
CPR in the breast and nodes 
0 0 1  1 
Median time to recurrence in 
months 
0 0 4.8 4.8 
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3. 9 Mortality from triple negative breast cancer 
 
 The mortality rate was 19.26% and was highest in the youngest group of patients 
(31.82%).  The time to death from time of diagnosis for all patients ranged from 5.1 to 
87.4 months.  
 
Table 16. Mortality rates  
 
 Very young 
(<35) 
n=22 
Young 
(≤40) 
n=34 
Older 
(>40) 
n=101 
All 
 
n=135 
p value 
Mortality     0.465 
All cause 7 (31.8%) 8 ( 23.5%) 18 (17.8%) 26 (19.3%)  
      
Time to death 
in months 
     
Range 9.5 – 56.0 9.5 – 73.7 5.1 – 87.4 5.1 – 87.4  
Mean 30.6 40.4 35.1 36.5  
Median 30.4 30.9 25.53 30.6  
      
Disease 
progression 
prior to death 
5 (71.43%) 5 (62.5%) 10 (55.56%) 15 (57.69%)  
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Table 17. Mortality according to stage at presentation 
 
 IA 
 
n=27 
IB 
 
n=2 
IIA 
 
n=31 
IIB 
 
n=32 
IIIA 
 
n=20 
IIIB 
 
n=18 
IV 
 
n=5 
p value 
        0.010 
Deaths 0 1  7  3  7  6  2   
Alive 27 1  24  29  13  12  3   
 
 
 
 
 
 
.4 
.6 
.8 
1 
.4 
.6 
.8 
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1 3 5 7 9 1 3 5 7 9 1 3 5 7 9 
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Graphs by St present 
By Stage 
Figure 5: Proportions of Survivors by  
Proportion Surviving 
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Table 18 . Mortality according to lymph node positivity at presentation 
 
 Lymph node 
negative 
 
n=60 
Lymph node 
N1 
 
n=57 
Lymph node 
N2 and N3 
 
n=18 
All 
 
 
n=135 
p value 
     0.265 
Deaths 10  10  6  26   
Alive 50  47  12  109   
0.00 
0.25 
0.50 
0.75 
1.00 
0 2 4 6 8 10 
Analysis time 
Cancer_Stage = IA & IB Cancer_Stage = IIA 
Cancer_Stage = IIB Cancer_Stage = IIIA 
Cancer_Stage = IIIB Cancer_Stage =  IV 
By Stage 
Figure 6: Kaplan Meier Estimates 
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Table 19. Mortality according to response to neoadjuvant chemotherapy 
 
 Deaths Alive p value 
    
Response to neoadjuvant chemotherapy 
n=62 
11 (18%) 51 (82%) 0.680 
No response to neoadjuvant chemotherapy 
n=73 
15 (21%) 58 (79%)  
    
CPR in the breast alone after neoadjuvant 
chemotherapy 
n=29 
4 (14%) 25 (86%) 0.400 
No CPR in the breast alone after 
neoadjuvant chemotherapy 
n=106 
22 (21%) 84 (79%)  
    
CPR after neoadjuvant chemotherapy 
n=11 
1 (9%) 10 (91%) 0.372 
No CPR after neoadjuvant chemotherapy 
n=124 
25 ( 20%) 99 (80%)  
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Table 20. Mortality according to surgical procedure 
 
 Breast conserving surgery 
n=68 
Mastectomy 
n=61 
No surgery 
n=6 
p value 
    0.003 
Deaths 8 (12%) 14 (23%) 4 (67%)  
Alive 60 (88%) 47 (77%) 2 (33%)  
 
 
0.00 
0.25 
0.50 
0.75 
1.00 
0 2 4 6 8 10 
Analysis time 
Br_surg = BCS Br_surg = Mastectomy 
Br_surg = None 
By Type of Surgery 
Figure 7: Kaplan Meier Estimates 
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Chapter 4.  Discussion 
 
Triple negative breast cancer is an aggressive subtype of breast cancer, associated with 
advanced stage at presentation, early recurrence and increased mortality.  It is a breast 
cancer subtype of interest to clinicians as there is still incomplete understanding of the 
cancer biology, no optimal treatment and poor outcomes.  The challenge remains to 
improve the outcomes in this complex and heterogeneous breast cancer subtype. 
 
Triple negative and Her2 over expressing breast cancers are the two most aggressive 
subtypes of breast cancer.   The five year disease free and overall survivals of patients 
with Her2 over-expressing breast cancer has improved dramatically with the use of 
monoclonal antibodies targeted against Her2 (65).  At present there is no targeted 
therapy to achieve similar improvements in outcome for triple negative breast cancer.  
Disease free and overall survival is poorer for any patient with triple negative breast 
cancer than the other breast cancer subtypes, regardless of age, stage at presentation 
and management. 
 
Triple negative breast cancers are a heterogeneous group of cancers and many units 
throughout the world are reassessing the patients seen, with special reference to patient 
demographics, and outcomes both loco-regional and metastatic.  
 
Early studies demonstrated triple negative breast cancer to be more common in North 
American  and European Black African women (26,30).  The number of publications 
regarding triple negative breast cancers in East, West and North Africa has increased 
noticeably.  These describe high incidences, late stage at presentation and poor 
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outcomes (9,33).  Studies have investigated genetic links between African-American and 
Sub-Saharan African breast cancer patients and postulate that there is a genetic link 
(66).  To date there is no published data regarding triple negative breast cancers in 
Southern Africa. 
 
Young women with breast cancer tend to present with an advanced stage of disease 
and a poor prognosis despite intensive treatment. It is postulated that the poor outcomes 
in young women with breast cancer are due to overrepresentation of aggressive 
subtypes.  An alternate theory is that there are genetic differences with increased 
expression of aggressive cancer genes resulting in breast cancer with unique biology. It 
is not clear if young women with triple negative breast cancer have poor outcomes 
because of their age or because of the subtype of breast cancer (50). 
 
This study aimed to determine the incidence of triple negative breast cancer at two 
specialist breast units and to assess presentation and outcomes as well as any 
differences related to the age of patients at presentation. 
 
 Milpark Hospital is a private facility that caters to insured and private paying patients.   
The Helen Joseph Hospital is a public sector hospital that treats an uninsured 
population. A study at both units found that black women comprised only  8% of all 
patients at Milpark Breast Care Unit, but  48% of all patients at Helen Joseph. There 
were 53% of patients at Milpark who had a tertiary education versus 13% at Helen 
Joseph (67). 
 
The two units are multidisciplinary units involving the same surgeons although the rest of 
the multidisciplinary team varies between the two units.  
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Limitations 
 
This was primarily a retrospective file review subject to certain limitations.   
 
It was not possible to assess the patients from Helen Joseph Hospital comprehensively 
as the data regarding staging and management were not readily available.  This resulted 
in a large number of patients being excluded. 
 
The study reviewed patients seen over a ten-year period, during this time the criteria for 
receptor status and classification and staging systems have changed.  There is, 
therefore, potential for bias due to subtype misclassification and stage migration.   
 
The majority of data collected was from the retrospective file review.  Reasons for 
incomplete data collection included: 
•  Patients who were referred after surgery and their pre-operative information 
were not available.   
• Patients who did not follow up at the practice and it was not possible to contact 
them, this included patients referred from overseas for whom travel to South 
Africa was not feasible and patients who followed up with their oncologist.   
• Patients who were seen for a second opinion and then followed up with their 
initial healthcare provider. 
• Patients who chose not to have traditional medical management. 
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The final sample size for analysis was 135 patients; hence some variables were 
unsuitable for significance analysis as the sample was too small.   
 
A further limitation of this study is that certain data are not part of routine history and 
examination, for instance, ethnicity.  It was thus unfortunately not possible to determine 
the ethnicity of the patients in this study, which is regrettable as ethnicity has been 
proposed as a major risk factor for triple negative breast cancer (29). 
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4. 1 Incidence of triple negative breast cancer  
 
Incidence rates of triple negative breast cancer vary throughout the world, and even 
within a country the rates may vary.  The incidence of triple negative breast cancer 
ranges from 10 to 20%, and as high as 55% in one study (9,29). 
 
The present study established that 14.4% of the women diagnosed with breast cancer 
had the triple negative subtype.  The incidence was 16.1% at Helen Joseph Hospital and 
13.9% at Milpark Hospital.  The total number of patients with breast cancer seen at 
Helen Joseph Hospital during the study period was 491 of which 79 patients had the 
triple negative subtype.   In the cohort at Milpark Breast Care Centre 1407 patients were 
evaluated, of which 196 had triple negative breast cancer. 
 
Previous studies indicated that the highest incidence of triple negative breast cancer is in 
premenopausal African-American and African women.  Population based studies 
demonstrated that women with triple-negative breast cancers were significantly more 
likely to be black or Hispanic and under the age of 40 years (15,28).  These findings 
were replicated in a study done in British women (30).  Certain countries have a lower 
incidence of triple negative disease, such as Sweden where the incidence is 12% (20), 
and in Japanese women the incidence is as low as 10% (29). 
 
The first study in Africa to be published by Huo et al (9), examined triple negative 
disease in Nigeria and Senegal and showed an incidence of 55%. The incidence of triple 
negative breast cancer in subsequent studies varies was 16.5% in Morocco (32), 27.9% 
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in Kenya (33), and 46% in Mali (34).  No studies in South Africa have been published as 
yet. 
 
The incidence of 14.4 % is less than the findings in the Carolina Breast Cancer Study – 
which had a prevalence of 20% basal like breast cancer (28). It is, however, more than 
the study from California where the incidence was 12.5% triple negative breast cancer 
(15) and the study by Dent et al (68), where the incidence was 11.2%.  The incidence in 
this study is similar to that in a study from Morocco, where the incidence of triple 
negative breast cancer was 16.5% (32). 
 
This is differs from other studies showing an increased incidence in African populations 
which may reflect that the study was done in an urban centre in a population with access 
to private healthcare.  The results may be different if the study were conducted in a rural 
area or hospitals serving low income areas (69).  It has been postulated that the 
increased incidence in young African-American women may be related to socio-
economic factors and different access to screening and treatment (28).  
 66 
4. 2 Age and menopausal status at presentation 
 
There was a wide range of age at presentation, from 18 to 108.  Patients over the age of 
40 years compromised 101 of the 135 patients (74.81%) and 34 patients were 40 years 
old or younger (25.19%), 22 were 35 years old or younger (16.30%).  The median age of 
the patients in the study was 54.  This is very similar to the California study of triple 
negative breast cancer where the median age at presentation was 54 (15) and a 
Slovenian population where the median age was 55 (24).  The median age at 
presentation of patients in our study was older than two studies in African patients, a 
Moroccan study where the median age at presentation was 46 years (32), and a 
Nigerian cohort, where the median age at presentation was 47 years old (70). 
 
Dent et al (68), looked at the differences in presentation between triple negative breast 
cancers and cancers positive for any of ER, PR or Her2.  They showed that patients with 
triple negative breast cancer were younger at presentation – 53 vs. 57.7 years with a p 
value of ≤ 0.0001.  In this study 25% of women were 40 years old or younger, which is 
similar to the study by Liedtke et al (51) where 21.1% of the patients with triple negative 
breast cancer were younger than 40.   
 
The 135 patients were assessed for menopausal status at presentation and 58% were 
postmenopausal.  Premenopausal patients formed 36% and perimenopausal 6% of the 
cohort.  Breast cancer is often a disease of postmenopausal women, confirmed by Kwan 
et al (71), where 76% of patients with luminal breast cancers were postmenopausal, but 
in triple negative breast cancers only 64% of patients postmenopausal, although they did 
not include perimenopausal women.   
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4. 3 Stage and tumour characteristics at presentation  
 
In this study stage Ia tumours were more frequent in patients over the age of 40 years 
(21%).  In patients 40 years old and younger 18% of patients had stage Ia tumours, a 
difference more pronounced in women 35 years old or younger, where 13.65% had 
stage Ia tumours.  This difference was not, however, significant with a p value of 0.518.   
 
In the women older than 40 years, as the stage at presentation advanced, the number of 
patients affected decreased.  In the younger patients the greatest proportion of patients 
had stage IIB tumours at presentation.  This was again more pronounced in women 35 
years old or younger, 41% compared to 35% in women 40 years old and younger.  In 
stage IIIa and IIIb the number of patients was lower in all age groups.  It is interesting to 
note that in this cohort only women older than 40 years of age presented with stage IV 
disease. 
 
There are well-described prognostic and predictive factors in breast cancer to estimate a 
patient’s outcome, and guide management. Prognostic factors in breast cancer include 
time-dependent prognostic variables, biological prognostic variables and patient-related 
variables such as age and menopausal status. 
 
Time-dependent prognostic variables include tumour size, lymph node stage, and extent 
of distant tumour spread. Biological prognostic variables are intrinsic tumour biological 
characteristics that determine tumour behavior and response to therapy.  They are 
assessed using morphologic surrogates such as tumour differentiation, proliferation 
status and growth rate. Biologically aggressive tumours are more likely to present at an 
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advanced stage and the majority of advanced tumours show poor biological prognostic 
features.  Advanced stage at presentation and aggressive biology are major factors 
associated with the poor outcomes of triple negative breast cancer patients.   
 
The association of triple negative disease with advanced stage at presentation is well 
documented (8). Studies have shown that triple negative breast cancers are more likely 
to be larger, node positive (54.4% vs. 45.6%), and have grade III nuclear grade (66% vs. 
28%) (68).  This is similar to the findings of Rais et al (32), from in Morocco and one of 
the most recent studies published (24). 
 
The poor prognosis of breast cancer in young women is linked with a number of factors 
that include: large tumour size at diagnosis, higher tumour grade, mitotic rate and lymph 
vascular invasion (47).   It is unclear if advanced stage at presentation is intrinsic to 
breast cancers in young women or related to other factors such as breast cancer 
subtype (72). 
 
The Helen Joseph Hospital and Milpark Hospitals both have a multimodality approach to 
the management of breast cancer.  Patients are initially diagnosed and staged with a 
triple assessment, starting with a clinical examination.  Patients are sent for both a digital 
mammogram and ultrasound, although young patients and those with dense breasts 
may only have ultrasound assessment.  If a suspicious lesion is seen on imaging, a core 
biopsy is done. Magnetic resonance imaging may be used in certain patients, especially 
young patients. 
 
An important aspect of the initial staging is the assessment of axillary nodes.  If clinically 
or radiologically there is nodal involvement this is confirmed with a fine needle aspiration 
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or core biopsy.  If there is no nodal involvement after initial assessment the patient has a 
dye and gamma probe guided sentinel lymph node biopsy.   
 
In this study most patients had tumours between zero and five centimeters (86%), and 
45% of all patients had tumours of two to five centimetres.  Younger patients tended to 
present with larger tumours, the most marked difference was in tumours larger than five 
centimetres.  Only 10% of patients older than 40 years old had tumours greater than five 
centimetres and 18% of patients 40 years old or younger and 23% of patients 35 years 
old or younger.  Lesions that were T4 (involving skin, chest wall or both), were more 
common in women older than 40 years (15%) than women 40 years or younger (12%).   
This difference was not significant with p = 0.352.  
 
If T4 tumours are excluded 58% of all patients had primary tumours larger than two 
centimetres.  In the group of patients 40 years old and younger 68% had tumours larger 
than two centimetres, with little difference in women 35 years old and younger (68%).  
This corresponds with studies showing that younger women present with bigger 
tumours. 
 
Tumour size is an independent predictor of recurrence, especially in patients without 
lymph node involvement.  There is an increase in recurrence rates with increasing size, 
tumours greater than two centimeters are associated with 20% recurrence rates (73).  
Studies of triple negative breast cancer describe that patients presented with 
significantly larger tumours – 22 vs. 17 mm in the California Study (15).   
 
Early breast cancer is defined by the National Cancer Institute as stage I, II and IIIa 
cancer.   If this definition is used, then the majority of women 35 years old and younger 
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(91%) and women 40 years old and younger (88%) presented with early breast cancer.  
This suggests that younger women present with less advanced disease, which is 
contrary to most current evidence.   
 
The behaviour of breast cancer, however, is based on a number of factors of which 
lymph node involvement is a significant prognostic indicator (73).  Lymph node 
involvement is associated with increased local recurrence rates (5.5% vs. 24.7%) and 
poorer disease-free and 5-year survival (75).  The association with poorer disease-free 
and overall survival rates holds true even for lymph node metastases of 2 mm or less, 
and lymph node positivity does not correlate with tumour size (68,76). 
 
Axillary lymph nodes were positive at presentation in 56% of all patients assessed; 13% 
had more than three nodes positive.  This is much higher than the 10.7% lymph node 
positivity in luminal A breast cancer (77).  The overall rate of positive lymph nodes was 
almost identical between patients 40 years and younger (56%) and those older than 40 
years (55%) (p=0.276).  The incidence, however, was higher in women 35 years and 
younger (64%).  This is consistent with studies that have shown significant associations 
between lymph node involvement and age at presentation (78). 
 
Tumour grade assesses gland formation, nuclear features and mitotic activity, and is 
also a significant prognostic factor in breast cancer outcomes; it strongly correlates with 
both progression free and overall survival (60).  There is a correlation between grade 
and 5 year disease free survival with a relative risk of recurrence of 4.4 in grade 3 
compared to grade 1 (79).   
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It was not possible to determine nuclear grade on all patients so only 121 of the 135 
were analysed.  It is a reflection of the aggressive biology of triple negative breast 
cancer that 73% of all patients assessed in the study had grade 3 tumours.  There was 
no clear pattern: in patients 35 years old and younger 77% had grade 3 tumours and in 
patients 40 years old and younger 71% had grade 3 tumours.  This proportion was 
similar to patients over 40 years old, where 74% of patients had grade 3 tumours.  
 
This cohort of patients has demonstrated a trend to an association between presentation 
at a more advanced stage, larger tumours, and more lymph node involvement with 
younger age at presentation especially in in patients 35 years old and younger. In the 
study by Liedtke et al in 2013 (78), they showed that younger patients with triple 
negative breast cancer were more likely to have grade 3 tumours, as well as lymph node 
positive disease. 
 
Seven patients with ductal carcinoma in situ or no tumour found in the breasts were 
excluded from analysis. Two patients with no tumour found in the breast were older than 
40 years and presented with axillary masses that were lymph nodes on imaging and 
breast cancer on biopsy. The significance of the triple negative subtype in in situ 
tumours is not clear as the study of biomarkers are in their relative infancy in DCIS and 
key prognostic and predictive markers associated with invasive breast cancer have not 
been adequately studied in DCIS (74).  Five patients with metastatic disease were also 
excluded; they were all over the age of 40 years, ranging in age from 53 to 79 years old.   
 
The other predictors of recurrence such as lymphovascular invasion and proliferative 
markers are not reported, as the data were not available on sufficient patients for 
meaningful analysis. 
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. 
This study assessed a population with some uniformity in patient education level, 
socioeconomic status and equivalent access to healthcare.  Despite this there was a 
trend to differences in stage at presentation and tumour characteristics between women 
40 years and younger and women older than 40 years. 
 
It is interesting to note that the trend to locally advanced disease at presentation persists 
in a more privileged cohort at Milpark Hospital. This may be due to the aggressive nature 
of triple negative breast cancer rather than delayed presentation due to poor access to 
healthcare. 
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4. 4 Surgery for the breast primary 
 
Almost all of the patients had surgical resection of their breast cancer  (96%) and half of 
all patients had breast conserving surgery (50%).  There is, however a difference in the 
type of surgery that a patient had according to age at presentation as younger patients 
tended to have more aggressive surgery, although the difference was not significant.  In 
the group of patients 35 years old or younger 64% had a mastectomy, in contrast to 56% 
of women 40 years old and younger, and 43% had a mastectomy in the group of 
patients older than 40, the p value was 0.172. 
 
The difference in surgical approach according to age is a reflection of the concerns 
about recurrence after breast conserving surgery in young patients (80).  There is no 
indication for more aggressive surgery in triple negative breast cancer on its own.  This 
is supported by several studies which have demonstrated no significant differences in 
the local control rates between triple negative breast cancer and the other subtypes 
when breast conserving surgery was carried out (81).  A study from 2011 showed 
increased local recurrence in patients with triple negative breast cancer treated with 
mastectomy than breast conserving surgery.  They related this to an increased benefit 
on recurrence rates from adjuvant radiation post breast conserving surgey (82). 
 
Younger patients with breast cancer especially patients 35 years and younger have an 
increased risk of locoregional recurrence after breast conserving surgery than older 
patients (83).  The increased locoregional recurrence is probably multifactorial but the 
morphologic characteristics of breast cancer in young patients in a significant factor (84). 
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4. 5 Neoadjuvant and adjuvant therapy 
 
The main modalities of treatment for breast cancer are: surgery, chemotherapy, 
hormonal therapy, targeted therapy and radiation therapy.  The indications for each 
modality are based on tumour characteristics, patient characteristics, surgeon and 
oncologist approach, and patients’ concerns and choices. 
 
Prognostic factors such as lymph node involvement and tumour size are commonly used 
for decision-making regarding neo-adjuvant and adjuvant therapy.  It is a reflection of the 
number of adverse prognostic factors in this group of patients that almost two-thirds had 
neo-adjuvant chemotherapy (60%).  Age is another important factor in the decision to 
give neo-adjuvant chemotherapy, and 71% of patients 40 years and under had neo-
adjuvant chemotherapy versus 55% of women older than 40 years.  This was not a 
significant difference, p=0.120. 
 
Neoadjuvant chemotherapy is also indicated for downstaging of tumours for breast 
conserving surgery.  In this cohort there was equivalent number of patients having 
mastectomies to those having breast conserving surgery, thus downsizing to offer breast 
conserving surgery does not appear to have been a major indication for neoadjuvant 
chemotherapy. In the group of younger patients who were more likely to have a 
mastectomy, they were also more likely to have neoadjuvant chemotherapy.  This 
decision was based on tumour characteristics and poor prognostic factors.   
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The number of patients having neoadjuvant chemotherapy is an indicator of the 
proportion presenting with locally advanced disease or adverse prognostic features such 
as stage, age and tumour grade. 
 
Neoadjuvant chemotherapy is not routine in all units managing breast cancer.  Protocols 
may differ according to factors such as limited access to adjuvant therapy or sentinel 
lymph node biopsies; and the preferences of the multidisciplinary teams.  A number of 
patients in the cohort were referred from other units and were offered adjuvant treatment 
if indicated. 
 
There were 55 patients who did not receive neoadjuvant chemotherapy, of whom 49 
(89%) received adjuvant chemotherapy. The indications for adjuvant chemotherapy were 
based on the findings of the surgical specimen histology, patient factors and discussion 
in the multi-disciplinary meeting.   
 
Adjuvant therapy consisted of chemotherapy and radiation therapy.  Hormonal therapy 
was not offered to patients, as they were negative for oestrogen and progesterone 
receptors.  The number of patients who had adjuvant treatment reflects the aggressive 
biology of the tumours reviewed in this study. In the group of all patients 117 (87%) had 
adjuvant therapy, of these 55 patients (41%) had chemotherapy and 93 (69%) had 
radiation therapy.  There was no significant difference according to age at presentation, 
p=0.371. 
 
Adjuvant chemotherapy was given to 41% of all patients, but there was a difference 
according to age at presentation.  Patients who were 40 years and younger had adjuvant 
chemotherapy in 29%, and 27% of patients 35 years and younger.  This is contrast to 
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45% of patients over 40 years old; in this study older patients were more likely to receive 
chemotherapy after surgery.   
 
The number of patients who had either neoadjuvant or adjuvant chemotherapy was 128 
of 135 patients (95%).  When analysed in this way patients older than 40 years old were 
slightly more likely to have chemotherapy (96%) than women 40 years old and younger 
(91%). 
 
There was seven patients who had both neoadjuvant and adjuvant chemotherapy.  This 
suggests particularly aggressive disease.  The seven patients comprised three patients 
40 years or younger, of whom two were 35 years old and younger, and four patients 
older than 40 years. 
 
In the Milpark breast cancer unit multidisciplinary team adjuvant radiation is prescribed 
for:  breast conserving surgery, involvement of more than three nodes, extra nodal 
spread, tumour size greater than five centimeters, insufficient   margins and T4 tumours.  
The team accepts 10 millimetres as a clear margin.  
 
Adjuvant radiation therapy was given to 69% of all patients and the proportions were 
similar despite different age at presentation.  Women older than 40 years old had 
adjuvant radiation in 68%, women 40 years and younger in 71% and women 35 years 
and younger 73%.  
 
It may be argued that one of the primary reasons for adjuvant radiation therapy is breast 
conserving surgery.  In this cohort of 135 patients 93 (69%) had adjuvant radiation 
therapy, 56 (60%) of these patients had breast conserving surgery.  The ratio for 
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younger women is, however, different to the entire cohort.  Patients who were 35 years 
old and younger had radiation therapy after mastectomy in 63% and patients 40 years 
and younger in 54%.  Patients older than 40 years old had adjuvant radiation therapy 
after mastectomy in 35%.  This suggests that the indication for radiation therapy was 
other factors such as: tumour size, grade and lymph node status.  
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4. 6 Multimodality treatment 
 
It can be seen that most of the cohort had multimodality treatment of their breast cancer.  
4% of all patients had surgery alone and some of these declined adjuvant chemotherapy 
or radiation therapy for personal reasons.  When all patients were assessed, 90% had 
surgery and chemotherapy, 69% surgery and radiation therapy and 67% had all three 
modalities.  This illustrates two features of triple negative disease: the aggressive tumour 
biology, and the lack of targeted therapy.   
 
Patients older than 40 years old (68%) and those 40 years or younger (67%) were 
equally likely to have three modalities of treatment.  Patients who were 35 years old or 
younger, however, were more likely to have multimodality treatment – 73%.  These 
numbers reflect the increased rate of radiation therapy in patients 35 years or younger.  
The trend to multimodality treatment in young patients reflects a more aggressive 
approach to treating breast cancer in these women because of the known poorer 
outcomes and the benefit of adjuvant radiation therapy in triple negative breast cancer. 
 
In the current literature triple negative breast cancers have the poorest outcomes of all 
the subtypes.  The progression-free and breast cancer specific survivals of the luminal A 
and B subtypes can be significantly improved by the addition of hormonal blockade such 
as tamoxifen (85).  The Her2 overexpressing subtype had the poorest outcomes before 
the use of trastuzumab and more recently lapatinib and pertuzumab (86).  The 
introduction of targeted therapy has improved the disease-free progression and overall 
survival of Her2 overexpressing tumours from 75% and 87% to 81% and 92% 
respectively (65).  
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There is as yet no targeted therapy available for triple negative breast cancers.  The poly 
(ADP-ribose) polymerases (PARPs) were investigated as targeted therapy for triple 
negative breast cancers but did not show efficacy in phase III trials.  There has been an 
explosion of research into potential targets and agents for the management of this 
subtype.  A number of potential targets have been identified such as: epidermal growth 
factor receptors (EGFR); vascular endothelial growth factor and its receptors (VEGF, 
VEGFR); DNA repair capacity - PARPs, epigenetic regulation, androgen receptor (AR) 
and folate receptor (FR) signaling; and mammalian target of rapamycin (mTOR) 
inhibitors (44).  
 
The number of patients requiring more than one modality of treatment and the 
persistently poor outcomes highlights the need for better and more treatment options. 
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4. 7 Tumour response to neoadjuvant chemotherapy 
 
In this cohort 80 patients (59%) had neoadjuvant chemotherapy.  The majority (91%) of 
these patients responded in some manner – clinically, radiologically, pathologically or a 
combination thereof.  This may reflect the nature of the chemotherapy given as most 
patients were given anthracycline and taxane based regimens, which are associated 
with optimal outcomes (87).   The patients 35 years old and younger had a marginally 
better response (94%). 
 
The triple negative subtype, grade and age of patients in this study may account for the 
complete pathological response in the breast in 29 patients (36%) of the 80 patients who 
had neo-adjuvant chemotherapy.  It is important to note that not all patients had a 
response in both the breast and lymph nodes; only 11 patients (14%) had a complete 
pathological response in both breast and nodes.   In the data on outcomes it can be 
seen that patients who still had viable cancer cells in their lymph nodes after 
neoadjuvant chemotherapy had worse outcomes than the patients who did not. 
 
There was a non-significant difference in complete pathological response according to 
age at presentation, p=0.254.  Patients who were 35 years old and younger had higher 
rates of complete pathological response with 56% in the breast, 19% in the lymph nodes 
and 19% in both the breast and lymph nodes.  In the group of patients 40 years old and 
younger the rates of complete pathological response were 46% in the breast, 17% in the 
lymph nodes and a poorer rate of 13% for both breast and lymph nodes.  The patients 
who were older than 40 years old had the worst complete pathological response in the 
breast at 32%, but a better response in the lymph nodes at 16%. In these patients the 
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response rate of 14% in both the breast and lymph nodes was better than the patients 
40 years old and younger. 
 
Complete pathological response to neoadjuvant chemotherapy has been associated with 
improvement in disease-free and overall survival, which translates to long-term clinical 
benefit.  Complete pathological response translates to improved survival with a 0.36 risk 
of death and 5 year overall survival rates of 83.9% and 5 year disease-free survival rates 
of 83.4% compared to 67.4% and 50% respectively (91).  The definition of complete 
pathological response, however, is not standardized.  Some studies define complete 
pathological response as no tumour found in the breast or lymph nodes, some studies 
only include the absence of tumour in the breast and not in the nodes, and some studies 
include in situ disease as complete pathological response.  This has led to variations in 
the estimation of benefit of complete pathological response on clinical outcomes (88). 
The greatest benefit is shown when there is complete response in the breast and the 
lymph nodes (92).  Some studies have shown that complete pathological response in the 
primary breast tumour predicts response in the axillary nodes (93).    
 
In a study of Turkish patients, factors that predicted complete pathological response 
were grade, menopausal status, triple negativity, percentage of ER positivity, and Her2 
expression (89). The benefit of complete pathological response is not seen in all 
subtypes of breast cancer. The three subtypes predictive of benefit from complete 
pathological response are: luminal B Her2 negative patients, Her2 overexpressing 
patients and triple negative breast cancer patients (88).   Triple negative breast cancer 
treated with chemotherapy and Her2 overexpressing breast cancer in patients treated 
with trastuzumab demonstrate the greatest benefit on long term clinical outcomes after 
complete pathological response (90).  In the triple negative breast cancer subtype there 
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may be further variations in rates of complete pathological response according to which 
of the subtypes of triple negative breast cancer is present.   
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4. 8 Recurrence of triple negative breast cancer 
 
In the present study 23% of all patients had disease progression after initial 
management. There was a greater recurrence rate in patients 40 years old and younger 
(32%) than patients older than 40 years old (20%), p =0.215.  This difference was more 
pronounced in women 35 years and younger (36%).  In the study by Dent et al (68), the 
recurrence rate for triple negative breast cancer was 34% vs. 20% for other breast 
cancer subtypes.  The recurrence rate for  all patients in this study was lower, this may 
be due to a smaller cohort as Dent et al reviewed 180 patients; or shorter follow up time.  
This cohort may also be different in terms of population group. 
 
The triple negative breast cancer subtype is associated with shorter relapse free survival 
times and a trend to visceral metastases (5,94).  Many other studies have confirmed 
these poor outcomes; they have also shown that recurrences in triple negative breast 
cancer occur earlier than the other breast cancer subtypes.  Dent et al (68), 
demonstrated high rates of recurrence in the first four years after diagnosis and no 
recurrences after eight years from diagnosis.  This was confirmed in the present study 
(tables 11 and 12).  
 
Breast cancer in young women is a recognized risk factor for recurrence and poor 
outcomes regardless of subtype.   Women 40 years old and younger have a 1.53 (95% 
CI 1.37-1.74) increased risk of recurrence than women older than 40 years (46). A key 
question in breast cancer management is whether young patients do poorly because 
they have preponderance to aggressive subtypes such as triple negative breast cancer 
or whether breast cancer in the young has unique biology (50).  This study determined 
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outcomes according to age in the subtype of triple negative breast cancer to assess if 
the poor outcomes of younger women with breast cancer persisted when compared to 
older women with the same aggressive subtype.  This is a similar question to the study 
done by Liedtke et al at the MD Anderson Cancer Center (78), and it appears that age at 
presentation may be an independent predictor of outcome regardless of subtype. 
 
Although the difference in recurrence rates according to patient age was not significant 
(p=0.215), it was one of the most marked differences in this cohort. Some studies have 
attributed the poorer disease free survival rates in younger women to increased local 
recurrence in young women treated with breast conserving surgery (95).  In this study, 
however, most patients 40 years old and younger had a mastectomy, and there was still 
a high rate of local recurrence despite more aggressive surgery. 
 
Distant recurrences accounted for almost half of all recurrences (14 out of 31).  
Recurrences outside the breast occurred in 22 patients (16%).  This corresponds with 
data showing that there is a defined pattern of locoregional recurrence in triple negative 
breast cancer.  Dent et al (68), found that locoregional recurrences occurred in 25% of 
triple negative breast cancers as opposed to 44% of the other subtypes.  A difference 
was again seen according to age with women 35 years and younger having 23% of 
recurrences outside the breast.  The rate was 21% in women 40 years old and younger 
and 15% in women older than 40 years old.  
 
Six patients had recurrences at more than one site and two had recurrences in both 
regional lymph nodes and distant sites. This suggests that triple negative breast cancer 
is a systemic disease with early micrometastases.  This is consistent with other studies 
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that have postulated that the predominant mode of spread in triple negative breast 
cancer is haematogenous with a tendency to develop visceral metastases early (24). 
 
Early recurrence is a recognized feature of triple negative breast cancer and in the whole 
cohort the median time to recurrence was less than two years (23 months).  The range 
was 4.5 – 75 months in women 40 years and younger and 5 – 92 months in women 
older than 40 years.  Recurrences in younger women occurred within 6 years with a 
median of 23 months, and while the median in older women was 19 months there were 
still recurrences after seven years.  It is similar to the findings of Dent et al that no 
recurrences occurred after eight years (68).   
 
The two patients with the longest time to recurrence in women 40 years old and younger 
were 54 and 74 months.  They both presented with early breast cancer – stage I and IIb, 
had breast conserving surgery, chemotherapy and radiation therapy.   The patient with 
the longest time to recurrence in the group of women 40 years and older had stage IIa 
cancer treated with breast conserving surgery, chemotherapy and no radiation therapy.    
This patient had a better outcome than younger women despite less aggressive 
treatment. 
 
The results of this study are similar to other studies, which have shown that the peak risk 
of recurrence of triple negative breast cancer is within three years (24).   Studies have 
also shown a significant correlation between age at diagnosis and both disease free 
survival and distant disease free survival.  The MD Anderson Cancer Centre data show 
a 30% greater risk for recurrence in younger patients, comparing women younger than 
40 to women older than 40 (78). 
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The recurrence rates, site and time to recurrence are in contrast to the luminal A subtype 
where the proportion of patients with disease progression is both less and the 
progression is later.   Patients with luminal subtypes have a 0.38 (CI 0.23-0.61) relative 
risk of developing locoregional recurrence after surgery compared to triple negative 
breast cancers (96). 
 
Recurrence was analysed according to stage at presentation, this showed a significant 
difference (p=0.010) showing increased recurrence rates with more advanced stage at 
presentation.  There was almost a doubling of the recurrence rate as the stages 
progressed from I to II and then to III.  The exception is the recurrence in both the 
patients with stage IB cancer at presentation.  Both of these patients were older than 40 
years, had neoadjuvant treatment and mastectomies.  One patient developed metastatic 
disease within a year of diagnosis and died 13 months after diagnosis – this may reflect 
particularly aggressive disease and the poor prognosis associated with lymph node 
positivity.  
 
The impact of lymph node positivity on recurrence was assessed.  It is a significant 
finding (p=0.008) that lymph node positive disease was associated with a three times 
increased rate of recurrence. 
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4. 9 Response to neo-adjuvant chemotherapy and 
recurrence 
 
There were 80 patients treated with neoadjuvant chemotherapy and 24 (30%) had a 
recurrence.  This proportion was similar in all ages at presentation.  The median time to 
recurrence in all patients treated with neoadjuvant chemotherapy was 18 months.  There 
was a difference in time to recurrence according to age at presentation with younger 
patients presenting with recurrences earlier.  Women 35 years old and younger had a 
median time to recurrence of 11 months, in women 40 years old and younger time to 
recurrence was 15 months and 19  months in women older than 40 years. 
 
The recurrence rates in patients who had neoadjuvant therapy differed with the degree 
of pathological response.  The recurrence rate was 10% in all patients if there was no 
viable tumour found in the breast and 1.25% if there was no viable tumour found in the 
breast and lymph nodes. Patients who were 40 years old and younger had a 29% 
recurrence if treated with neoadjuvant chemotherapy, if there was a complete 
pathological response in the breast alone the recurrence rate was 13% at a median time 
to recurrence of 25 months.  When these patients had a complete pathological response 
in both breast and lymph nodes there were no recurrences.  These data were similar for 
women 35 years old and younger.  The only recurrence after complete pathological 
response in both breast and lymph nodes was in a patient older than 40 years who had 
breast conserving surgery and no adjuvant radiation therapy.  Radiation therapy reduces 
the ten year risk of recurrence after breast conserving surgery from 35.0% to 19.3% 
(97). 
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The difference in recurrence rate according to the degree of pathological response is in 
agreement with international trends.    
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4 .10 Mortality 
 
The overall mortality rate for the 135 patients was 19%.  Age at presentation did affect 
the mortality rate.  Women who were 40 years and younger had a mortality of 23%, and 
women older than 40 years had a mortality of 17%.  This was not a significant difference 
– p value 0.465. 
 
Studies of triple negative breast cancer have showed poor 3 year progression free and 
overall survival rates (41).  A study in London comparing triple negative breast cancer to 
all other subtypes showed a 5 year survival of 62% for triple negative breast cancer and 
75% for all other patients.  Survival in the triple negative group was better for those 
patients who had both surgery and chemotherapy (8).  A similar study in Ljubljana found 
a 5 year disease free survival of 68.2% and 5 year overall survival of 74.5% (24).  
 
 A large study from the MD Anderson Cancer Centre on triple negative breast cancers 
describes median survival according to age groups.  The worst overall survival was in 
the 31-40 age group, followed by the younger than 30, 41-50, older than 60 and 51-60 
age groups in that order (78). 
 
The effect of stage at presentation on mortality was assessed as it was for recurrence.  
The association was also significant (p=0.010) with an approximate 10% increase in 
mortality with increase in stage from I to II, III and IV.  The outlier is again the patient 
with stage IB cancer who died 13 months after diagnosis.  Stage IIB is also remarkable 
for a lower than expected mortality rate (4%), especially as the mortality rate for stage 
IIA cancer was 23%. 
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It is contrast to the significant association of lymph node positivity with recurrence, there 
was not a significant association with mortality (p=0.265).  The difference in mortality 
rate between lymph node negative and up to three lymph nodes positive was less than 
one percent.  There was, however, a doubling of mortality rate if more than three lymph 
nodes were positive.  
 
Neoadjuvant chemotherapy did not affect mortality rates in a significant manner 
(p=0.680), as mortality was 18% if there was some response to chemotherapy and 21% 
if there was none.   There was an impact on mortality, however, if there had been a 
complete pathological response.  The benefit was greater if there was complete 
pathological response in the breast and lymph nodes (9%) than just the breast (14%). 
 
It is interesting to note that the mortality of patients who had had a mastectomy was 
double that of patients having breast conserving surgery.  This is especially interesting 
as a number of the patients having a mastectomy were younger.  
 
One of the most significant findings of this study was the significant impact of not having 
surgery on mortality (p=0.003).  Patients who did not have surgery had a mortality rate 
three times those having a mastectomy and six times those having breast conserving 
surgery.  This may not reflect the impact of surgery on survival alone.  The women who 
did not have surgery were likely to have advanced disease such as metastatic spread.  
Their mortality was thus determined by the extent of their disease not the surgery or lack 
thereof.  Evidence indicates that triple negative breast cancer has earlier 
haemotogenous spread, thus the significant impact of a local intervention is noteworthy, 
however the numbers are small and definitive conclusions cannot be made.   
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Chapter 5: Conclusion 
 
This study looked at breast care units at two hospitals in South Africa to assess the 
prevalence and outcomes of triple negative breast cancer and the impact of age at 
presentation. 
  
This study of South African women did not demonstrate the higher incidences described 
in other studies with a large cohort of black women especially in West Africa. The 
incidence was similar to a number of other studies in Africa, and higher than studies in 
North America, Europe and Asia. 
 
It has been postulated that the presentation and outcomes in triple negative breast 
cancer are related to socioeconomic issues. Patients in this study tended to present with 
advanced disease despite the majority coming from an insured population with good 
access to health care.  This suggests that factors other than socio-economics contribute 
to the more advanced stage at presentation.   
 
Triple negative breast cancer is marked by poor outcomes and lack of effective 
treatment. The majority of patients in this study required multimodality treatment.  
Radiation therapy was often indicated for reasons other than breast-conserving surgery.  
This not only indicates the aggressive nature of triple negative breast cancer but also 
that a mastectomy does not mean that a patient does not require radiation. 
 
The patients with triple negative breast cancer in our study showed a variable response 
to neoadjuvant treatment.  Those patients with a complete response to neoadjuvant 
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treatment had better progression free and overall survival.  The different response of the 
breast and the lymph nodes to neo-adjuvant treatment has a prognostic implication.  
Patients who did not have a complete pathological response in the lymph nodes as well 
as the breast had poorer outcomes.  This is consistent with international opinion that 
complete pathological response to neoadjuvant treatment is only significant if there is no 
viable tumour in the breast or lymph nodes. 
 
One of the debates in breast cancer surgery is whether young patients with breast 
cancer do poorly because of preponderance to aggressive subtypes or if breast cancer 
in young patients has a unique biology. This study looked at one subtype and assessed 
whether the differences according to age persisted within one subtype and found that 
they do.  The findings were in accord with other studies investigating triple negative 
breast cancer and age at presentation. 
 
In our cohort presentation and outcomes differed with age at presentation.  Younger 
patients presented with larger, more poorly differentiated tumours, and were more likely 
to have lymph node involvement at presentation. This was associated with shorter 
recurrence free survival and higher mortality rates despite more aggressive treatment.  
Younger patients were more likely to require neoadjuvant chemotherapy and 
multimodality treatment.  
 
In the analysis of the data the patients were categorised into two groups – those 40 
years old and younger and those older than 40 years.  A subgroup of the younger 
patients was also analysed, those patients 35 years old and younger.  Tests of 
significance were done on the groups 40 years and younger and older than 40 years.  
This was based on previous studies showing that age at presentation became an 
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independent predictor of outcome at the age of 40.  Studies investigating the 
significance of age at presentation do, however, use other age cutoffs.  In our study the 
differences in presentation, management and outcomes were greater when the group of 
patients 35 years old and younger were analysed.   
 
Future studies to assess age and stage at presentation in the other breast cancer 
subtypes would demonstrate if this phenomenon is limited to triple negative breast 
cancers only. It would also be interesting to look at a triple negative cohort and use 
immunohistochemistry markers for basal breast cancer and proliferation.  It may then be 
determined that the differences in presentation, management and disease progression 
between the young and the older patients are related to differences in the subtype of 
triple negative breast cancer.  
 
This cohort of patients demonstrates that triple negative breast cancer is a disease with 
aggressive tumour biology and poor outcomes.  Age at presentation appears to affect 
presentation and outcomes independent of breast cancer subtype.  
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Appendix 3 
 
TRIPLE NEGATIVE BREAST CANCER STUDY 
DATABASE 
2010 
 
PATIENT CHARACTERISTICS 
 
Name:_______________________________________________________ 
Date of birth:________________________ Age:_____________________ 
Sex:  Female ⃞  Male ⃞ 
Ethnicity:  White ⃞ Black   ⃞ Coloured  ⃞  Indian  ⃞ 
 European  ⃞ Chinese  ⃞ Other   ⃞ 
Menopause:  Pre   ⃞ Peri  ⃞  Post  ⃞     
Diagnosis:________________________________________________________ 
Date of diagnosis:__________________________________________________ 
Age at diagnosis:__________________________________________________ 
Personal history of breast cancer: _____________________________________ 
Family history of breast cancer: _______________________________________ 
Family history of ovarian cancer: ______________________________________ 
Family history of other cancers: _______________________________________ 
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TUMOUR CHARACTERISTICS 
Date mass first noticed: 
________________________________________________ 
Histology:  DCIS  ⃞   Infiltrating ductal ca  ⃞   Infiltrating lobular ca  ⃞Other  ⃞ 
Differentiation:  Poorly  ⃞ Moderately ⃞   Well  ⃞      Cannot be assessed  ⃞  
Lymphovascular invasion:   Yes⃞ No⃞ 
Markers:   ER pos  ⃞ neg  ⃞ %positivity _______ 
 PR pos  ⃞  neg  ⃞ 
 Her2 pos  ⃞  neg  ⃞ FISH  ⃞ 
 Grading:_____________________________________________________  
Laterality: Left  ⃞  Right  ⃞    Bilateral  ⃞ 
Axillary node status: 
 Method: SLNB  ⃞    ALND  ⃞  USS ☐       Biopsy  ☐ 
 Date:_____________________________________________________ 
 Number of glands involved:_________________________________ 
 Number of glands examined:_____________________________________ 
Staging: Clinical: 
 T_________    N_______      M_______   Tumour size_________ 
 Pathological: 
 T_________  N_______    M_______      Tumour size________ 
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NEOADJUVANT MANAGEMENT 
Neoadjuvant treatment given:  Yes  ⃞ No  ⃞ Unknown  ☐  
Chemotherapy:   Yes  ☐ No  ☐ 
 Regimen:_________________________________________________ 
 Number of cycles:_________________________________________ 
 Number of cycles before surgery:____________________________ 
Hormonal:  Tamoxifen  ⃞ AI  ⃞ None  ☐ 
 Date start:_________________ Date end:______________ 
 Ongoing:  ⃞ 
Radiation:  Yes  ⃞ No  ⃞ 
Target:  Herceptin    None    
Response to neoadjuvant treatment:   
 Clinical        Radiological    Pathological          None    
 
SURGICAL MANAGEMENT 
BCS     Mastectomy      Other    
Date of surgery:___________________________________________________ 
SLNB +/- sampling    ALND       None    
Date of surgery:___________________________________________________ 
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ADJUVANT MANAGEMENT 
Adjuvant treatment given:  Yes    No:     Unknown    
Chemotherapy:  Yes    No    
 Regimen:_________________________________________________ 
 Number of cycles:_________________________________________ 
Hormonal:  Tamoxifen    AI    None    
 Date start:_________________ Date end:______________ 
 Ongoing:    
Radiation:  Yes     No    
Target:  Herceptin    None    
 
BREAST CANCER RELAPSE 
Relapse:  Yes   No:    
Date of relapse:_______________________________________________ 
Local:     Yes    No     
  Clinical diagnosis:    Yes    No    
  Pathological proof obtained:  Yes    No    
 Date:_____________ 
Regional:     Yes    No     
  Clinical diagnosis:    Yes    No    
  Pathological proof obtained:  Yes    No     Date:_____________ 
 
Distant:    Contralateral breast cancer      
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   Liver     Lung      CNS    
   Skin     Other      Bone    
Pathological proof obtained:  Yes      No       Date:___________________ 
 
SECONDARY PRIMARY CANCER 
Contralateral breast cancer          Endometrial cancer           Ovarian cancer    
Leukamia           Other    
 
SURVIVAL DATA 
Alive: Yes    No         
Date of 
death:___________________________________________________________ 
Cause of 
death:_________________________________________________________ 
 
DISEASE FREE SURVIVAL 
Disease progression:  Yes     No    
Date of 
progression:_____________________________________________________ 
Date last 
seen:__________________________________________________________ 
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Appendix 4 
 
TRIPLE NEGATIVE BREAST CANCER STUDY 
TELEPHONIC FOLLOW UP  
VERBAL CONSENT  2013 
 
Hello Ms_____________, I am ______________________.  I am calling you 
from the Milpark Breast Care Centre regarding your diagnosis of breast cancer. 
 
We are doing a study on the prevalence and outcomes of women with breast 
cancer that does not respond to hormones or Herceptin, or triple negative breast 
cancer.  The aim of the study is to understand how many women in South Africa 
have triple negative breast cancer and how it affects them.  The study is part of a 
Masters of Medicine in the Department of Surgery at the University of the 
Witwatersrand.  It is anonymous and has ethics approval.  The first part of the 
study looked at the files of all the breast cancer patients seen at the Milpark 
Breast Care Centre.   
 
We would like to find out what has happened to you since your last follow up, by 
asking you a short questionnaire. Your management will not change whether you 
choose to answer or not and regardless of your answers. 
 
Do you understand the purpose and implications of the questionnaire and do you 
wish to continue with the questionnaire? 
Yes    No    
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Appendix 5 
 TRIPLE NEGATIVE BREAST CANCER 
STUDY TELEPHONIC FOLLOW UP 
QUESTIONNAIRE 
2013 
 
Date:__________________________________  
Time:________________________________ 
Verbal consent obtained:   Yes  ⃞        No  ⃞ 
Patient requests email of information sheet:  Yes  ⃞  No  ⃞ 
Patient email address:____________________________________________________ 
Patient identity confirmed:  DOB  ⃞ Address   ⃞         Diagnosis   ⃞ 
 
Questions: 
Are you well?      Yes  ⃞ No  ⃞ 
Have you had a recurrence of your breast cancer? Yes  ⃞ No  ⃞ 
If yes  
when?________________________________________________________________ 
Where?_______________________________________________________________ 
Have you been diagnosed with a cancer other than breast cancer?   
Yes  ⃞       No  ⃞ 
If yes – where?__________________________________________________________ 
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Appendix 6 
 
List of corrections 
 
1. The results would benefit from regression analysis especially of the results are 
going to be published (as the study should be).  This would determine important 
predictors of survival/recurrence. 
Thank you for your valuable comments, the regression analysis will indeed help 
determine predictors of outcome.  This will be performed in phase two of the study as 
part of the preparation for publication. 
 
2. The discussion has unnecessary duplication of the introduction. 
This has been duly noted and the discussion amended accordingly.   
For example: page 64, paragraph 2- the results of three studies have been consolidated 
and summarised. 
  Page 66, paragraph 1 – the results of three studies have also been 
consolidated. 
  Page 69, paragraph 2  - The results of various studies have been 
summarised into one sentence. 
 
3. In the discussion moving the main study findings to the beginning of each section to 
provide context should be considered. 
The comments are appreciated and the text has been revised accordingly, thank you for 
the constructive criticism. 
For example:  page 65, paragraph 2 has been moved to page 64, paragraph 2. 
Page 69, paragraph 4 to page 70 paragraph 1 has been moved to page 
68, paragraph 1. 
Page 82, paragraph 3 to page 83, paragraph 1  has been moved to page 
81 paragraph 2. 
page 84,paragraph 3 has been moved to paragraph 1 on the same page. 
page 85, paragraph 4 has been moved to page 84 paragraph 2. 
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4. Study limitations are normally described toward the end of the discussion.  The 
candidate has outlined these early in the discussion to give context.  Positioning 
early in the discussion detracts from the study findings. 
 
Thank you for your constructive input, the value of the comments has been noted and 
reviewed with the supervisor.  After much discussion it was felt that the results may 
difficult to interpret without the context of the limitations being described, and the order 
has been left unchanged. 
 
5. Avoid repeating results in the discussion. 
The text has been amended to clarify the implication and impact of results as opposed to 
repeating them without interpretation.  
For example:  page 74, paragraph 1 – context has been given to the rate of mastectomy 
in women 35 years old and younger by comparing it to the lower rates in older women. 
  Page 75, paragraph 2 – the rate of neo-adjuvant chemotherapy has been 
compared between the different age groups. 
 
6. For the purpose of the Research report, a one page Turnitin plagiarism report 
summary should suffice, especially when the percentage similarity is low. 
This revision has been noted and the full Turnitin plagiarism report amended to a one 
page summary as suggested. 
 
7. Minor errors 
Thank you for your constructive criticism and assistance with editing, all comments have 
been accepted and changes made to correct errors. 
 
 
